Patent · US Active

Minimal UTR sequences

US11981910B2 · kind B2 · utility

0Cited by

1References

16Claims

0Family size

Assignee

ethris GmbH · DE

Inventors

Christian Plank · Wien, AT
Carsten Rudolph · Krailling, DE
Manish Kumar Aneja · Munich, DE
Ludwig Weiss · Kissing, DE

Key dates

Filing date	Jun 6, 2022
Grant date	May 14, 2024
Priority date	—
Expiry date	Jun 6, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2840/105
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Described are DNA molecules which can be transcribed into an mRNA harbouring novel UTR sequences combining the advantages of being extremely short and at the same time allowing for high translation efficiencies of RNA molecules containing them. Further, described are vectors comprising such a DNA molecule and to host cells comprising such a vector. Moreover, described are corresponding RNA molecules containing such UTRs. Further, described is a pharmaceutical composition comprising the described RNA molecule and optionally a pharmaceutically acceptable carrier as well as to the use of the described UTRs for translating a coding region of an RNA molecule into a polypeptide or a protein encoded by said coding region.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.